ArticleBMC urology2025
Clinical outcomes and prognostic factors in patients undergoing radical nephrectomy with lymphadenectomy for pN1 renal cell carcinoma.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Chemokines CCL3 and CCL7 as Complementary Diagnostic Biomarkers Across Tumor Grades in Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to evaluate the clinical effectiveness of radical nephrectomy combined with regional lymphadenectomy in patients with locally advanced renal cell carcinoma (RCC) at the pathological N1 stage.
methodsWe retrospectively analyzed clinical data from a cohort of 112 patients diagnosed with locally advanced RCC at the pathological N1 stage who underwent radical nephrectomy between June 2012 and June 2024. The indications for LND in this study were preoperative imaging suggesting lymph node enlargement (short diameter ≥1 cm) or intraoperative suspicion of metastasis; the scope of dissection followed the anterior template (including lymph nodes from the renal hilum to the level of the inferior mesenteric artery). The analysis included univariate and multivariate Cox proportional hazards regression models, as well as Kaplan-Meier survival curves.
resultsThe cohort comprised 112 patients with pT1-4N1M0 RCC, with a mean age of 49 years (±14) and consisted of 74 males and 38 females. Among these patients, 32 had stage pT1-2 cancer, while 80 presented with more advanced stages (pT3 and above). The median follow-up time was 51 months (range: 12-110 months), with 101 (90.2%) patients completing follow-up and 11 (9.8%) lost to follow-up by the end of the study. The median number of lymph nodes dissected during surgery was 8.0 (range 4.0-13.0), and the median number of pathological lymph node metastases was 2.0 (range 1.0-6.0). The postoperative complication rate was 5.4% (6/112), with 5 (4.5%) Grade II and 1 (0.9%) Grade III complications according to the Clavien-Dindo classification. Throughout the follow-up period, tumor progression was observed in 58 patients, including 9 cases of local recurrence and 54 cases of distant metastasis. The median relapse-free survival (RFS) was approximately 0.90 years (range 0.35-2.60 years), while the median overall survival (OS) was about 2.25 years (range 1.15-4.10 years). The 1-, 3-, and 5-year RFS rates were 44.6%, 21.5%, and 12.1%, respectively, and the corresponding OS rates were 78.5%, 36.8%, and 17.2%. Multivariate analysis identified sarcomatoid differentiation (P=0.001) and postoperative tumor progression (P=0.001) as independent risk factors for poor overall survival. Preoperative lymph node enlargement was identified as an independent risk factor for distant metastasis (P=0.038), while multigroup regional lymph node metastasis was linked to an increased risk of local recurrence (P=0.031).
conclusionPatients with lymph node metastatic locally advanced RCC exhibit a high risk of postoperative recurrence and metastasis, leading to a poor prognosis. Consequently, these patients require close monitoring and follow-up. Key adverse factors associated with tumor recurrence or poor survival identified include preoperative regional lymph node enlargement, sarcomatoid differentiation, and postoperative tumor progression in stage N1 RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.